The global myasthenia gravis treatment market size was valued at USD 2.32 billion in 2025 and is projected to grow from USD 2.55 billion in 2026 to USD 5.49 billion by 2034, registering a CAGR of 10.05% during the forecast period from 2026 to 2034. North America dominated the myasthenia gravis treatment market with a market share of 42.5% in 2025.
Myasthenia gravis treatment refers to the therapies used to manage myasthenia gravis, a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue by disrupting communication between nerves and muscles. The market includes cholinesterase inhibitors, corticosteroids, immunosuppressants, monoclonal antibodies, intravenous immunoglobulin (IVIG), plasma exchange therapies, and emerging targeted treatments. Market growth is driven by rising disease awareness, improved diagnostic capabilities, and advancements in precision immunotherapies.
Download a Free Sample To learn more about this report,
Growing Shift Toward Broader FcRn-Targeted Treatment
Myasthenia gravis therapy is increasingly moving toward FcRn inhibition because this approach lowers pathogenic IgG antibodies involved in disrupting neuromuscular transmission. Recent development is extending these therapies beyond specific antibody-positive groups toward broader patient populations, including patients whose commonly tested antibodies are not detected. This expansion is strengthening myasthenia gravis treatment market trends by increasing the number of patients potentially eligible for targeted therapy and reducing dependence on broad immunosuppression.
Increasing Development of More Convenient Self-Administered Treatments
Treatment developers are focusing on delivery systems that reduce dependence on hospital-based intravenous administration. Subcutaneous injections and pre-filled devices can give appropriate patients greater flexibility in managing chronic therapy while potentially reducing healthcare-resource requirements. This shift specifically addresses treatment convenience rather than expanding eligible antibody populations. Increasing emphasis on patient-controlled administration is therefore supporting myasthenia gravis treatment market demand for therapies with simpler long-term delivery.
Growing Treatment Options for Adolescents Expand the Addressable Patient Population
Historically, several advanced gMG therapies were initially developed and approved primarily for adults, leaving younger patients with fewer targeted options. Extending modern therapies to adolescents can reduce reliance on older immunosuppressive approaches and provide treatment based more directly on disease mechanisms. Pediatric and adolescent label expansion is therefore supporting myasthenia gravis treatment market growth by broadening the clinically eligible population for advanced biologic therapies.
Safety Concerns Can Slow Adoption of Highly Intensive Immune Therapies
Advanced immune-modifying approaches may potentially deliver deeper disease control but can also introduce safety risks requiring intensive monitoring. This is particularly important for cell therapies that substantially alter immune-cell populations and can trigger serious inflammatory reactions. Safety events can cause clinical holds, extend development timelines, and make regulators and clinicians more cautious about adopting highly intensive treatments. These risks can restrain expansion of the myasthenia gravis treatment market size even when early efficacy signals are promising.
B-Cell Depletion Creates a Distinct Targeted Treatment Opportunity
B cells play an important role in the autoimmune processes responsible for producing pathogenic antibodies in myasthenia gravis. Therapies targeting specific B-cell populations therefore provide a mechanism distinct from FcRn inhibitors and complement blockers. Expanding therapeutic diversity can help physicians select treatments according to individual disease biology and previous response. Companies establishing differentiated B-cell approaches can strengthen their myasthenia gravis treatment market share while providing additional options for patients with persistent disease.
Maintaining Durable Disease Control Without Continuous Treatment Remains Difficult
The myasthenia gravis treatment industry continues to face the challenge of achieving sustained symptom control because many targeted therapies suppress specific components of the autoimmune process without permanently eliminating the underlying disease. Patients may therefore require repeated infusions, injections, or treatment cycles over extended periods. Developers must balance durable efficacy with infection risk, treatment burden, and long-term immune-system effects when designing therapies for a chronic condition.
Ocular MG Dominated the Market with 54.3% Share in 2025
The ocular myasthenia gravis (MG) segment accounted for the largest share of the global myasthenia gravis treatment market at 54.3% in 2025, with a market value of USD 1.26 billion, and is projected to grow at a CAGR of 7.9% during the forecast period. The segment leads due to the high prevalence of ocular symptoms as the initial manifestation of myasthenia gravis and increasing awareness of early diagnosis and treatment.
Request Customizationto receive a tailored report.
Autologous Hematopoietic Stem Cell Transplantation (HSCT) is Projected to Register the Fastest Growth at a CAGR of 8.6%
The autologous hematopoietic stem cell transplantation (HSCT) segment is expected to witness the fastest growth, registering a CAGR of 8.6% during 2026–2034. Growing clinical research, advances in stem cell therapies, and increasing interest in long-term disease management for severe and treatment-resistant myasthenia gravis are driving the growth of this segment. Meanwhile, the medication segment remained the largest in 2025, accounting for 48.6% of the market, with a value of USD 1.13 billion, owing to the widespread use of corticosteroids, immunosuppressants, and cholinesterase inhibitors.
Hospitals Dominated the Market with 56.7% Share in 2025
The hospitals segment held the largest market share of 56.7% in 2025, with a market value of USD 1.32 billion, and is projected to grow at a CAGR of 7.9% during the forecast period. The segment leads due to the availability of specialized neurology departments, advanced diagnostic facilities, multidisciplinary treatment teams, and access to complex therapies for myasthenia gravis patients. Meanwhile, academic research institutes are expected to register the fastest growth, with a CAGR of 8.4%, supported by increasing research activities and the development of innovative treatment approaches.
Speak to an Analystto discuss market opportunities.
North America dominated the global myasthenia gravis treatment market with a 42.5% share in 2025, representing a market value of USD 0.99 billion. The regional market is projected to grow at a CAGR of 7.6% during the forecast period. Growth is driven by the high diagnosis rate of myasthenia gravis, increasing adoption of advanced biologic therapies, strong healthcare infrastructure, and favorable reimbursement policies. Ongoing clinical research, growing availability of targeted treatments, and the presence of leading pharmaceutical companies continue to support regional market expansion.
The United States is the largest myasthenia gravis treatment market in North America due to its advanced healthcare system and high adoption of innovative therapies. Increasing availability of monoclonal antibodies, immunosuppressive drugs, and specialized neurological care is driving market growth. Strong investments in rare disease research, expanding clinical trials, and favorable reimbursement for advanced therapies further strengthen the market.
Canada is witnessing steady market growth due to improving diagnosis of rare neurological disorders, expanding access to specialized neurology centers, and increasing awareness among healthcare professionals. Government-supported healthcare programs, growing adoption of advanced immunotherapies, and ongoing investments in neurological research continue to contribute to market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 27.8% of the global myasthenia gravis treatment market in 2025, representing a market value of USD 0.64 billion. The regional market is expected to grow at a CAGR of 7.4% during the forecast period. Growth is supported by increasing awareness of autoimmune disorders, expanding access to innovative therapies, and continuous investments in neurological healthcare. Rising adoption of biologics and targeted treatments, along with favorable healthcare policies, is further driving regional market growth.
The United Kingdom is a leading market in Europe due to its well-established healthcare system and growing focus on rare disease management. Increasing access to specialized neurology clinics, expanding use of biologic therapies, and continued investment in clinical research are supporting market growth. National healthcare initiatives promoting early diagnosis and treatment also contribute to increasing demand.
Germany is experiencing significant market growth due to its advanced healthcare infrastructure and strong emphasis on neurological research. Increasing use of targeted therapies, expanding availability of specialized treatment centers, and ongoing pharmaceutical innovation are supporting market development. Favorable reimbursement policies and growing awareness of autoimmune disorders further encourage treatment adoption.
Asia Pacific held 21.6% of the global myasthenia gravis treatment market in 2025, representing a market value of USD 0.50 billion. The region is projected to register the fastest growth with a CAGR of 9.2% during the forecast period. Growth is driven by improving healthcare infrastructure, increasing awareness of rare neurological disorders, expanding access to advanced therapies, and rising healthcare expenditure. Governments are investing in better diagnostic capabilities and specialized neurological care, creating favorable opportunities for market expansion.
Japan is a key market due to its advanced healthcare system, aging population, and strong focus on neurological disease management. Increasing adoption of innovative biologic therapies, improved diagnostic technologies, and continued investment in rare disease research are driving market growth. The country's established reimbursement framework further supports access to advanced treatments.
China is witnessing rapid market growth due to expanding healthcare infrastructure, increasing awareness of autoimmune disorders, and rising investments in neurology care. Improved access to advanced treatment options, growing healthcare expenditure, and government initiatives to strengthen rare disease management are supporting market expansion. The country's large patient population also presents significant long-term growth opportunities.
Latin America accounted for 4.7% of the global myasthenia gravis treatment market in 2025, representing a market value of USD 0.11 billion. The regional market is expected to grow at a CAGR of 6.9% during the forecast period. Growth is supported by improving healthcare access, increasing awareness of autoimmune diseases, and expanding investments in neurology services. Governments and healthcare providers are working to improve diagnosis and patient access to advanced treatment options.
Brazil is the largest myasthenia gravis treatment market in Latin America due to its expanding healthcare infrastructure and growing investment in neurological care. Rising awareness of autoimmune disorders, increasing availability of specialized treatment centers, and improved access to advanced therapies continue to support market growth. Ongoing healthcare modernization initiatives are further strengthening treatment accessibility.
The Middle East and Africa accounted for 3.4% of the global myasthenia gravis treatment market in 2025, representing a market value of USD 0.08 billion. The regional market is projected to grow at a CAGR of 6.5% during the forecast period. Growth is driven by improving healthcare infrastructure, increasing awareness of rare neurological disorders, and expanding access to specialized healthcare services. Governments are investing in advanced diagnostic facilities and neurological treatment centers to improve patient outcomes.
The UAE is emerging as a leading market in the region due to increasing healthcare expenditure, expanding neurology centers, and growing adoption of advanced biologic therapies. Government initiatives to strengthen specialized healthcare services, along with investments in precision medicine and rare disease management, continue to support market growth.
Africa is witnessing gradual growth in the myasthenia gravis treatment market due to improving healthcare access, increasing awareness of autoimmune disorders, and expanding neurological care services. Investments in healthcare infrastructure, improvements in diagnostic capabilities, and greater availability of specialized treatments are expected to create new growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
LAMEA Lidocaine Market Size, Growth , 2026-2034
North America Neurodegenerative Disease Market Size, 2034
We are featured on:
sales@straitsresearch.com